Rephine helped transform our facility into a GMP compliant site ready for FDA inspection. Their expertise not only ensured compliance but also gave our teams the knowledge and confidence tosustain high-quality standards as we expand into OTC product manufacturing.
Client Testimonial
About this Case Study
A global cosmetics manufacturer, aiming to expand into the pharmaceutical space with over-the-counter (OTC) products, faced a critical challenge: achieving compliance with stringent US GMP (21 CFR 210–211) and FDA requirements. With limited internal GMP expertise, the site needed end-to-end guidance to prepare for inspection readiness and sustainable compliance.
Rephine partnered with the client to deliver a 12-month programme covering gap assessment, remediation, compliance readiness, and knowledge transfer. The result was a facility transformed into a GMP-compliant, FDA-ready site with empowered teams and a strengthened quality culture.
Key outcomes included:
- Successful FDA inspection readiness and site qualification for OTC production
- Expanded market access through new product opportunities
- Enhanced GMP knowledge and reduced compliance risks
- Sustainable quality culture embedded across departments
✅ Download the full case study to discover:
- How Rephine guided the site through GMP gap assessment and remediation
- The strategies used to achieve FDA inspection readiness within 12 months
- How compliance maturity enabled long-term growth and market expansion
Result: A compliant, inspection-ready site enabling OTC manufacturing and new business opportunities.
Download the Case Study
View our other resources and company news
A mid-sized pharmaceutical company embarked on a three-year digital transformation to validate TrackWise Digital across three sequential phases. See how full operational support within ValGenesis...
As regulatory demands grow, even strong QA teams reach their limits. Here is how flexible QA support helps pharmaceutical companies manage change, reduce risk and...
Rephine Barcelona S.L. is now accredited to ISO/IEC 17020 as an inspection body for specific GMP and GDP audit activities. We explain what the accreditation...
Relying on historical cleaning limits or visual cleanliness checks to justify shared manufacturing carries more regulatory risk than many sites realise. Find out what a...
Every change to a validated system carries risk. Discover the core components, roles and best practices that keep Change Management in CSV projects controlled, compliant...
A global cosmetics manufacturer wanted to enter the OTC pharmaceutical market but had zero GMP experience. In 12 months, their Spanish production site achieved full...
Turn data integrity findings into a sustainable, risk based remediation plan. A practical 7 phase framework for pharma labs....
Transport validation is a regulatory requirement under EU GMP Annex 15, yet many pharmaceutical companies still struggle with route selection and risk assessment. This guide...
Watch our webinar with Rephine and ValGenesis on modern, inspection-ready validation: what EU GMP Annex 11 and ALCOA+ now expect, and where AI fits in...